Stockscreener 앱 받기
5.92
8.78%
-0.57
시장 영업 전:
6.06
0.14
+2.36%
Helus Pharma Inc 주식(HELP)의 최신 뉴스
Helus Pharma appoints Michael Cola as CEO - The Pharma Letter
Helus Pharma Names Michael Cola As CEO For Next Phase Of Growth - bernama
HELUS PHARMA NAMES MICHAEL COLA AS CEO FOR NEXT PHASE OF GROWTH - bernama
Helus Pharma appoints Michael Cola as CEO amid clinical trial milestones By Investing.com - Investing.com South Africa
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution - wahanariau.com
Helus Pharma Appoints Michael Cola as Chief Executive Officer, Effective February 10, 2026 - marketscreener.com
Taking the Helm at Helus: A Brief Q&A With New CEO Michael Cola - Psychedelic Alpha
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market - Newswire Canada
Helus Pharma appoints Michael Cola as CEO amid clinical trial milestones - Investing.com Canada
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and ... - Caledonian Record
Will Helus Pharma's GAD Trial Data Calm Investor Anxiety? - RTTNews
Jefferies initiates Helus Pharma stock with Buy rating on upcoming catalysts - Investing.com Canada
Jefferies initiates Helus Pharma stock with Buy rating on upcoming catalysts By Investing.com - Investing.com South Africa
Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts Hold on GH Research’s 5-MeO-DMT IND; Compass Details Pivotal PTSD Trial Design; Cybin Becomes Helus - Psychedelic Alpha
Breakthrough or Bubble? The High-Stakes 2026 Readouts for Psychedelic Giants - geneonline.com
Psychedelic Funding, Public Markets, and M&A in 2025 - Psychedelic Alpha
The Psychedelic News Feed: January 1218, 2026 - Psychedelic Alpha
Definium points the way forward as MindMed drops old identity - Fierce Pharma
The Psychedelic News Feed: January 0511, 2026 - Psychedelic Alpha
Why Cybin (HELP) Is Down 9.1% After Rebranding To Helus And Relisting On Nasdaq - Yahoo Finance
Assessing Cybin’s Valuation As Helus Pharma Uplists To Nasdaq And Joins The Nasdaq Composite Index - Sahm
Helus Pharma Rings the Opening Bell - Nasdaq
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq - bernama
Helus Pharma Rebrands, Debuts On Nasdaq - bernama
Cybin (CYBN) Is Down 9.8% After Launching US$100M At-The-Market Equity ProgramWhat's Changed - simplywall.st
HELUS PHARMA REBRANDS, DEBUTS ON NASDAQ - bernama
Cybin (CYBN) Transitions to Helus Pharma and Moves to Nasdaq - GuruFocus
Cybin to Begin Nasdaq Trading Under New Ticker, Plans to Change Name to Helus Pharma - marketscreener.com
Helus Pharma Rebrands, Moves to Nasdaq as It Advances Late-Stage Mental Health Drugs - TipRanks
Cybin launches $100 million at-the-market equity program By Investing.com - Investing.com Australia
The New Psychedelics: One Dose, Eight Hours, a Therapist on Standby - Bloomberg
Cybin (CYBN) Receives a Buy from H.C. Wainwright - The Globe and Mail
Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq in Early January - TipRanks
Cybin to rebrand as Helus Pharma and shift US listing to Nasdaq - MSN
Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq - TipRanks
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq - Business Wire
Cybin to transfer listing from NYSE American to Nasdaq, rebrand - Investing.com
Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - Business Wire
Cybin to Participate in the Jefferies Global Healthcare Conference in London - Business Wire
Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025 - Business Wire
Cybin to Participate at the 2025 Milken Institute Future of Health Summit - Business Wire
Finance Watch: MapLight Brings US Biopharma IPO Tally To 11 In 2025 - Citeline News & Insights
Cybin announces $175 million registered direct offering - marketscreener.com
Cybin Announces $175 Million Registered Direct Offering - Business Wire
Cybin Stock: Optimism Quickly Fades (NYSE:CYBN) - Seeking Alpha
Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones - Business Wire
Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder - Business Wire
Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - Business Wire
Cybin to Participate in the Cantor Global Healthcare Conference 2025 - Business Wire
Cybin Announces Senior Leadership Changes - Business Wire
Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - Business Wire
Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - Business Wire
Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures - Business Wire
Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics - Business Wire
Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics - Business Wire
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder - Business Wire
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase - Business Wire
CYBN Stock Price, News & Analysis | Cybin - Stock Titan
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003 - Business Wire
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights - Business Wire
CYBN Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
1.24%
0.19%
자본화:
|
볼륨(24시간):